- We will send in 10–14 business days.
/images/books/13009913/9783036506302.jpg)
- Publisher: MDPI AG
- ISBN-10: 3036506306
- ISBN-13: 9783036506302
- Format: 17 x 24.4 x 3.7 cm, kieti viršeliai
- Language: English
- SAVE -10% with code: EXTRA
Marine Compounds and Cancer 2020 (e-book) (used book) | bookbook.eu
Reviews
Description
The very first marine-derived anticancer drug, Cytarabine (aka Ara-C, Cytosar-U(R)), was approved by the FDA in 1969 for the treatment of leukemia. At the beginning of 2021, the list of approved marine-derived anticancer drugs consists of nine substances, five of which received approval within the last two years, demonstrating the rapid evolution of the field. The current book is a collection of scientific articles related to the exponentially growing field of anticancer marine compounds. These articles cover the whole field, from agents with cancer-preventive activity, to novel and previously characterized compounds with anticancer activity, both in vitro and in vivo, as well as the latest status of compounds under clinical development.
EXTRA 10 % discount with code: EXTRA
The promotion ends in 21d.07:11:18
The discount code is valid when purchasing from 10 €. Discounts do not stack.
- Publisher: MDPI AG
- ISBN-10: 3036506306
- ISBN-13: 9783036506302
- Format: 17 x 24.4 x 3.7 cm, kieti viršeliai
- Language: English English
The very first marine-derived anticancer drug, Cytarabine (aka Ara-C, Cytosar-U(R)), was approved by the FDA in 1969 for the treatment of leukemia. At the beginning of 2021, the list of approved marine-derived anticancer drugs consists of nine substances, five of which received approval within the last two years, demonstrating the rapid evolution of the field. The current book is a collection of scientific articles related to the exponentially growing field of anticancer marine compounds. These articles cover the whole field, from agents with cancer-preventive activity, to novel and previously characterized compounds with anticancer activity, both in vitro and in vivo, as well as the latest status of compounds under clinical development.
Reviews